Article thumbnail

Bisphosphonates and risk of atrial fibrillation: a meta-analysis

By Seo Young Kim, Min Jung Kim, Suzanne M Cadarette and Daniel H Solomon
Topics: Research article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2875664
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A: The use of randomized controlled trials for pharmacoepidemiology studies.
  2. (1995). age distribution, and gender of patients with atrial fibrillation. Arch Intern Med
  3. (2007). Alendronate and atrial fibrillation.
  4. (2001). Altman D: Systematic reviews in health care. Second edition.
  5. (2009). Atrial fibrillation in fracture patients treated with oral bisphosphonates.
  6. (2002). Atrial fibrillation in the elderly: facts and management. Drugs Aging
  7. (2009). Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord
  8. (2009). Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis. Drug Saf
  9. (2001). Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem
  10. (2009). Cadarette SM: Osteoporosis treatments and adverse events. Curr Opin Rheumatol
  11. (2000). Choice of effect measure for epidemiological data.
  12. (2003). Chung MK: Inflammation as a risk factor for atrial fibrillation. Circulation
  13. (2009). Comment on: heterogeneity in meta-analysis should be expected and appropriately quantified.
  14. (2006). Corticosteroids and the risk of atrial fibrillation. Arch Intern Med
  15. (1996). Ensrud KE: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet
  16. (2007). FDA: Update of safety review follow-up to the October 1,
  17. Foundation: America's Bone Health: The state of osteoporosis and low bone mass in our nation [http://www.nof.org/ advocacy/prevalence/]
  18. (2008). Foundation: The clinician's guide to prevention and treatment of osteoporosis
  19. (2001). Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis.
  20. (2003). G: Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.
  21. (2008). JA: Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ
  22. (2006). Lip G: Is atrial fibrillation an inflammatory disorder? Eur Heart J
  23. (1986). N: Meta-analysis in clinical trials. Control Clin Trials
  24. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
  25. (2006). Opie L: Controversies in atrial fibrillation. Lancet
  26. (2009). Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS ONE
  27. (2009). Oral bisphosphonates and the risk of atrial fibrillation in a cohort of older adults. Pharmacoepidemiol Drug Saf
  28. (2008). Psaty B: Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med
  29. (2009). Relation of bisphosphonate Received:
  30. (2002). S: Quantifying heterogeneity in a meta-analysis. Stat Med
  31. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies
  32. (2005). Tosteson A: Incidence and economic burden of osteoporosis-related fractures in the United States,
  33. (2010). Tsai C: Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause
  34. (1998). What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes.
  35. (2007). Yearly zoledronic acid in postmenopausal osteoporosis.
  36. (2007). Zoledronic acid and clinical fractures and mortality after hip fracture.